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Objective: In vascular tissue, T-cadherin (T-cad) levels correlate with the progression of atherosclerosis, restenosis and tumour
neovascularization. This study investigates whether T-cad influences proliferation of vascular cells. Methods and Results: Cultures of
human umbilical vein endothelial cells (HUVEC) and rat and human aortic smooth muscle cells (rSMC, hSMC) were used. T-cad was
overexpressed in HUVEC and hSMC using an adenoviral expression system. In cultures released from G1/G0 synchrony parallel
immunoblot analysis of T-cad and cell cycle phase specific markers (p27Kip1, cyclin D1, E2F1, PCNA, cyclin B) showed increased T-cad
protein levels subsequent to entry into early S-phase with sustained elevation through S-and M-phases. T-cad was increased in G2/M-phase
(colchicine) synchronized cultures. In FACS-sorted cell populations, expression of T-cad in S-and G2/M-phase was higher than G1/G0-phase.
Compared with empty-and LacZ-vector infected controls, HUVEC and hSMC overexpressing T-cad exhibited increased proliferation as
assessed in enumeration and DNA synthesis assays. Additionally, following release from G1/G0 synchrony, HUVEC and hSMC
overexpressing T-cad enter S-phase more rapidly. Flow cytometry after BrdU/propidium labelling confirmed increased cell cycle progression
in T-cad overexpressing cells. Conclusion: In vascular cells, T-cad is dynamically regulated during the cell cycle and its expression
functions in the promotion of proliferation. T-cad may facilitate progression of proliferative vascular disorders such as atherosclerosis,
restenosis and tumour angiogenesis.
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1. Introduction importantly contributes to pathological tumour angiogene-Proliferation of vascular cells plays an important role in
progression of many vascular diseases. Abnormal vascular
smooth muscle cell (SMC) growth and migration stimu-
lated by endothelial cell (EC) and inflammatory cell-
derived growth factors and cytokines are critical steps in
formation of the atherosclerotic plaque, in neointimal
hyperplasia during bypass vein graft failure or during
restenosis after percutaneous transluminal angioplasty [1].
EC proliferation is necessary for restoration of blood
supply to ischaemic tissues through angiogenesis [2], and
through re-endothelialization, is beneficial to atherosclerot-
ic plaque stability [3]. However, excessive EC proliferation0008-6363/$ - see front matter D 2004 European Society of Cardiology. Publish
doi:10.1016/j.cardiores.2004.06.010
* Corresponding author. Tel.: +41-61-265-2422; fax: +41-61-265-2350.
E-mail address: Therese-J.Resink@unibas.ch (T. Resink).sis [2] and the neovascularization of atherosclerotic lesions
which is a cause of plaque instability, rupture and throm-
bosis [3].
Cell growth, motility, differentiation and survival are
greatly dependent on both cell–cell and cell–extracellular
matrix adhesive interactions. Cadherins, a major constituent
of cell–cell adherent junctions, are transmembrane receptors
that mediate calcium-dependent intercellular adhesion [4].
During embryogenesis, cadherins play an important part in
cell sorting, control of cell polarity and morphogenesis [4],
while in the adult, loss of cadherin-mediated adhesion can
cause cancer development and progression [5]. The partic-
ipation of the cadherins in formation of blood vessels and
maintenance of their structural integrity has been acknowl-
edged only more recently. VE-cadherin, an EC-specific
cadherin and the major component of endothelial adherent
junctions, is involved in vasculogenesis, angiogenesis, ECed by Elsevier B.V. All rights reserved.
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herin participates in the formation of abluminal adherent
junctions between ECs and pericytes during the early phase
of brain angiogenesis [7]. T-cadherin (T-cad, or H-cadherin,
cadherin-13) is an atypical cadherin widely expressed in the
cardiovascular system [8]. It lacks transmembrane and
cytosolic domains and is attached to the plasma membrane
by a glycosylphosphatidylinositol (GPI) anchor. Although
T-cad can mediate weak homophilic cell aggregation in
suspensions of transfected cells [9], accumulating evidence
suggests that T-cad might not function as a true intercellular
adhesion molecule. In contrast to classical cadherins, T-cad
is not concentrated at sites of cell–cell contacts, is expressed
on the luminal but not the baso-lateral surface of polarized
transfected cells [9,10], and undergoes re-distribution to the
leading edge in migrating vascular cells [10]. T-cad has also
been shown to function as a repulsive cue for motor-axon
projection in the embryonic nervous system [11] and to
induce cell de-adhesion and promote directed cell migration
in vascular cells [12].
Similarly to classical cadherins, T-cad has a lower expres-
sion profile in sporadic breast, prostate, colorectal, and lung
cancers, and tumour cells transfected with T-cad cDNA
exhibit decreased proliferative and invasive potential [13].
However, in vascular tissue the progression of atherosclero-
sis, restenosis and tumour neovascularization is attended
with marked increases in T-cad levels on the surface of EC
and SMC [8,14,15], suggesting rather a positive correlation
between T-cad expression on vascular cells and their motility
and growth. This study examines the relationship between
vascular cell expression of T-cad and proliferation.2. Methods
2.1. Cell culture
The use of animal and human material in this study
conforms with the Guide for the Care and Use of
Laboratory Animals published by the US National Insti-
tute of Health (NIH publication no. 85-23, revised 1996),
and the principles outlined in the Declaration of Helsinki.
Human umbilical vein EC (HUVEC) were purchased from
PromoCell (Heidelberg, Germany) and normally cultured
in basal EC growth medium containing low serum (2%
FCS) and EC growth supplement (PromoCell). For
HUVEC, all tissue culture surfaces were pre-coated with
0.1% gelatine. HUVEC were used at passages 2–6 during
which expression of markers (von Willebrand factor, CD
31, VE-cadherin) for differentiated EC remained steady.
Rat and human aortic smooth muscle cells (rSMC and
hSMC) were isolated and phenotypically characterized in
primary cultures as described previously [16]. rSMC
(passages 6–13) were normally cultured in Dulbecco’s
modified essential medium supplemented with 10% fetal
calf serum (FCS), 10 mM TES/HEPES (pH 7.3), 100 U/ml penicillin/streptomycin and 20 mM Glutamax (Invitro-
gen, Basel, Switzerland). The same medium with inclusion
of smooth muscle growth supplement (Cascade Biologics,
Portland, USA) was used for hSMC (passages 4–10).
Growth-arrest culture conditions were as follows: rSMC-
serum-free DMEM containing 0.1% BSA for 36 h with one
medium change after 18 h. hSMC-serum-free DMEM con-
taining 0.1% BSA for 24 h. HUVEC—in basal EC culture
medium containing 0.1% serum for 18 h. Growth-arrest
under these conditions was confirmed (90–95% of cells in
G1/G0 phase) by standard flow cytometry after propidium
iodide (PI) labeling and analysis using ModFit software.
2.2. Overexpression of T-cad
T-cad was overexpressed in HUVEC and hSMC using
Adeno-Xk Expression System (Clontech, Palo Alto, USA)
as described previously [12]. Viral titer was determined by
End-Point dilution assay. For infections, HUVEC and
hSMC in normal growth media were seeded at a density
of 1–2 104 cells/cm2, allowed to adhere and infected
overnight with empty, LacZ (Clontech-Becton Dickinson)
or T-cad containing adenoviral particles at a final approx-
imate concentration of 100 pfu/cell. Trypan blue exclusion
assay confirmed full viability of all infected cultures.
Infected cultures were rinsed, trypsinized (0.25% trysin/1
mM EDTA in PBS) and re-seeded into culture dishes
appropriate for any given functional assay. Expression
levels of characteristic differentiation markers for HUVEC
(von Willebrand factor, CD31, VE-cadherin) and hSMC
(smooth muscle a-actin, desmin) were equivalent in paren-
tal and infected cultures (data not shown).
2.3. Cell proliferation
For cell enumeration, HUVEC and hSMC infected with
empty, LacZ or T-cad containing adenoviral particles cells
were growth-arrested, re-seeded (2 103 cells/cm2) and
cultured for up to 6 days in normal culture media with
medium refreshment on days 2 and 4. Cell numbers were
determined daily by trypsinization and counting in a Coulter
counter. For DNA synthesis, infected HUVEC and hSMC
were re-seeded (2 103 cells/cm2), cultured normally for 2
days, and then growth-arrested. Thereafter cells were cul-
tured for a further 24 h in normal culture media containing
FCS, and DNA synthesis assessed by [3H]-thymidine incor-
poration assay [17].
2.4. Cell cycle
Cells were seeded (2.5 103 cells/cm2) and cultured
normally for 2 days before growth-arrest. Cultures were
released from growth-arrest by addition of normal culture
media. For immunoblotting, at selected consecutive inter-
vals cells were gently rinsed with PBS, lysed and analysed
for specific cell-cycle markers. For flow cytometry, 22 h of
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culture continued for a further 14 h, after which cells were
harvested by trypsinization, washed with PBS and resus-
pended in 70% ice-cold ethanol. Cells were labelled with
FITC-conjugated anti-BrdU (Becton Dickinson) and PI
according to protocols detailed by Becton Dickinson, and
analysed using a FACScalibur cytometer (Becton Dick-
inson, San Jose, CA, USA) and ModFit software. For
cycle blockade, cultures at 80% confluence were incubated
for 18 h without additions (control), or with inclusion of
0.1 mM colchicine or 10 mM hydroxyurea, washed
carefully with PBS, lysed and analysed by immunoblot-
ting. Viability of treated cultures was proven by trypan
blue exclusion and absence of active caspase 3 on immu-
noblots of cell lysates.
2.5. Cell sorting
rSMC at 70% confluency in 75-cm2 flasks were col-
lected after detachment by incubation in PBS containing 1
mM EDTA and 2 mM EGTA (PEE) for 10–15 min, at 30
jC, pelleted, resuspended in PBS and fixed by addition of
ice-cold ethanol (final 70%). Before sorting, cell suspen-
sions were washed twice with PEE, and resuspended (107
cells/ml) in PEE containing 0.1% Triton-X-100, PI (20 Ag/
ml) and DNAse-free RNAse (0.2 mg/ml). Cells were
sorted using a FACS Vantage SE cytometer (Becton
Dickinson). Phase integrity was verified by subjecting
aliquots of sorted populations to flow cytometry and
analysis using ModFit software. After lysis, equal amounts
(2 105 cells/lane) were analysed by immunoblotting
(available anti-T-cad antibodies not sufficiently sensitive
for use in FACS).
2.6. Immunoblotting
The method of immunoblotting has been described
previously [18]. Lysis buffer was PBS containing 1%
SDS, 1 mM PMSF, 2 Ag/ml pepstatin, 20 Ag/ml aprotinin,
30 Ag/ml bacitracin, protein concentrations were determined
using the Lowry method, and electrophoresis was in 8 % or
10% SDS-polyacrylamide gels under reducing conditions.
Protein loading equivalence was routinely controlled after
electrotransfer to nitrocellulose membranes by staining with
Ponceau S and by immunoblotting for actin and/or Gas
subunit. The following primary antibodies were used: rabbit
antibody against the first extracellular domain of T-cad
generated in our lab (1 Ag/ml) [8]; mouse anti-VE-cadherin
(clone 75; 2Ag/ml), anti-N-cadherin (clone 32, 2 Ag/ml),
anti-p27Kip1 (clone 57; 1:500), anti-cyclin D1 (clone DCS-6;
1:500), anti-E2F1 (clone KH95/E2F; 1:500), anti-cyclin B
(clone 18; 1:1000) all from BD Biosciences, San Diego,
CA, USA; mouse anti-PCNA (1:300, clone M870) and
rabbit anti-von Willebrand factor (1:200) from DAKO,
Glostrup, Denmark); rabbit anti-Ga (1 Ag/ml, Calbiochem,
Darmstadt, Germany); rabbit anti-cleaved caspase-3(Asp175) (1:500, Cell Signaling-New England Biolabs,
Frankfurt am Mein, Germany); mouse anti-actin (clone C-
2; 1:200) and rabbit-anti-CD31 (1:100) from Santa Cruz
Biotechnology, Santa Cruz, CA, USA; rabbit anti-desmin
(1:100) and mouse anti-smooth muscle a-actin (clone 1A4;
1:400) from Sigma-Aldrich Basel, Switzerland. Secondary
HRP-conjugated anti-rabbit IgG (1:5000) and HRP-conju-
gated anti-mouse IgG (1:5000) were from Southern Bio-
technology (BioReba, Reinach, Switzerland). Amersham
ECL (Amersham Biosciences, Little Chalfont, UK) and
the Enhanced Luminescence System or SuperSignal West
Dura from Pierce (Rockford, IL, USA) were variously used
for detection of immunoreactive proteins. Scanned images
of Ponceau S stains and autoradiograms were analysed
using AIDA Image or Scion (NIH) Image software. Figures
show representative autoradiograms from any given single
experiment.
2.7. Statistical analysis
Results are given as meanF S.D. Statistical analyses
were performed by One-way ANOVA followed by post
hoc Bonferroni’s multiple comparison when appropriate. A
P value of < 0.05 was considered significant.3. Results
3.1. T-cad expression during the cell cycle
In order to evaluate changes in T-cad expression during
cell cycle, we analysed levels of T-cad in parallel with
recognized markers of cell-cycle progression (p27Kip1,
cyclin D1, E2F1, PCNA, cyclin B). Subconfluent rSMC,
hSMC and HUVEC were first synchronized in G1/G0 by
serum deprivation (time 0), and after release from growth-
arrest by serum addition, protein levels were analysed in
cells collected at consecutive intervals. Fluctuations of the
different cell-cycle markers in rSMC (Fig. 1A), hSMC (Fig.
2B) and HUVEC (Fig. 2A) subsequent to release from
growth-arrest generally corresponded well to the literature
data (reviewed in Refs. [19,20]). Levels of both precursor
130 kDa and mature 105 kDa T-cad proteins were found to
increase subsequent to entry into early S-phase (down-
regulation of p27, upregulation of cyclin D1), and remained
elevated through both S-phase (E2F1, PCNA) and M-phase
(cyclin B) transit. Actin and/or Ga, used as internal con-
trols, remained steady throughout the growth period. Attes-
tation that alterations in levels of T-cad as measured in
whole cell lysates reflect changes in surface expression was
obtained by determining T-cad levels in membrane prepa-
rations [21] from HUVEC and hSMC at G1/G0 synchrony,
12 and 24 h after release from growth-arrest (insets above
T-cad panels in Figs. 1 and 2).
To confirm elevated expression of T-cad in M- and S-
phase cells, T-cad expression was examined after flow
Fig. 1. Cell-cycle-associated alterations in T-cad protein expression in rSMC. Panel A. The indicated proteins were analysed by immunoblotting of rSMC
cell lysates prepared at consecutive intervals after release from growth-arrest. Positive controls (lane S) included: CHAPS extract from human aortic media
for T-cad (105 kDa), HUVEC cell lysate for actin (40 kDa) and Ga (45 kDa), HeLa cell lysate for E2F-1 (60 kDa) and p27Kip1 (27 kDa), Jurkat cell lysate
for cyclin B (62 kDa) and cyclin D (36 kDa). The experiment was performed on three separate occasions. Panel B. Expression of T-cad, N-cadherin and Ga
in G1/G0-phase, S-phase, and G2/M-phase sorted rSMC populations. Three independent experiments were performed.
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S-phase or G2/M-phase populations. Due to the large
starting numbers of cells required in order to finally obtainsufficient quantities of pure-phase populations for immuno-
blot analysis, we investigated only rSMC. The results (Fig.
1B) show a greater (P < 0.001) expression of T-cad in S-
Fig. 2. Cell-cycle-associated alterations in T-cad protein expression in human vascular cells. Lysates of HUVEC (Panel A) and hSMC (Panel B) prepared at
consecutive intervals after release from growth-arrest were analysed by immunoblotting for the indicated proteins. Three independent experiments were
performed. The blots inset above the T-cad frames are of membrane isolates from cells collected at 0, 12 and 24 h.
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cells. Changes in N-cadherin (slight decreases vs. G1/G0)
and Ga (slight increases vs. G1/G0) were not significant.
3.2. T-cad expression in cells treated with hydroxyurea and
colchicine
T-cad protein expression was examined in cultures of
rSMC, hSMC and HUVEC after an 18-h treatment with
either 10 mM hydroxyurea (for accumulation of cells at G1/
S interface), or 0.1 mM colchicine (to induce accumulation
of cells at G2/M interface). Viability of cultures so treated
was proven by complete trypan blue exclusion and absence
of active caspase 3 on Western blots of cell lysates. In the
case of HUVEC and rSMC where many mitosing cells were
observed after colchicine treatment, the poorly attached
dividing cells (Fig. 3A–D, lanes 3b) were collected (after
gently tapping the dishes) and analysed separately from
attached non-dividing cells (Fig. 3A–D, lanes 3a). Culturesof hSMC displayed a much lower mitotic activity, and
although the amount of rounded cells in M-phase after
colchicine treatment was visibly higher than in untreated
cultures, we could not gather sufficient material for analysis
on Westerns. Therefore, colchicine-treated hSMC cultures
were very gently rinsed to minimize detachment of rounded
M-phase cells and dividing and non-dividing hSMC were
collectively analysed (Fig. 3A–C, lanes 3).
In hydroxyurea-treated cultures, T-cad levels remained
unchanged (HUVEC and hSMC) or slightly increased
(rSMC) as compared with control cultures (Fig. 3A, cf.
lanes 2 vs. lanes 1). Following colchicine treatment, we
observed a significant increase of T-cad protein in HUVEC
(left panel), hSMC (central panel) and rSMC (right panel)
that was due to a higher expression in poorly attached M-
phase cells (Fig. 3A cf. lanes 3b—detached cells vs. lanes
3a—attached cells). The effect of colchicine was most
prominent in rSMC which were the fastest growing of the
three cell types examined (Fig. 3A, right panel). In these
Fig. 3. T-cad expression is increased in M-phase of the cell cycle. Cells were incubated for 18 h in normal growth medium without additions (control,
lanes 1), or with 10 mM hydroxyurea (lanes 2) or 0.1 mM colchicine (lanes 3, 3a, 3b). In colchicine-treated HUVEC and rSMC (A–D, left and right
panels) rounded detaching cells in M-phase (lane 3b) were collected and analysed separately from attached cells (lane 3a). In colchicine-treated hSMC
(A–C, central panels), all cells were collectively analysed. T-cad (Panel A), PCNA (Panel B), Ga (Panel C) and VE- and N-cadherins (Panel D) were
analysed by immunoblotting. Expression is calculated relative to that (arbitrarily taken as 100%) under control conditions. Four independent experiments
were performed. Statistical analysis was performed by One-way ANOVA. Asterisks indicate where treated and control cultures differ significantly ( P at
least < 0.01).
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cells (lane 3b) increased by approximately three-fold as
compared to control (lane 1), while in attached non-dividing
cells (lane 3a) expression was two-fold less than in control
(the latter obviously comprising a mixture of cells at
different stages of the cell cycle). As in the foregoing
experiments, changes in T-cad were measurable in mem-
brane preparations (data not shown), confirming that alter-
ations in T-cad protein reflect changes in surface expression.Changes in proliferating cell nuclear antigen PCNA
(Fig. 3B) generally correlated with those of T-cad (Fig.
3A). Ga expression remained constant (Fig. 3C). Com-
pared with control cells, expression of classical VE- and
N-cadherins (Fig. 3D) was unchanged in hydroxurea-trea-
ted cells (lanes 2) but decreased by approximately 30–
40% after colchicine treatment in the detached M-phase
cells (cf. lanes 3b—detached cells vs. lanes 3a—attached
cells and lanes 1—untreated cells).
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To further investigate the apparent influence of T-cad on
cell proliferation, T-cad was overexpressed in cultured
HUVEC and hSMC using an adenoviral expression system.
The high level of surface T-cad expression (vs. controls)
and its stability throughout the experimental period was
proven by immunoblotting of membrane isolates (Fig. 4).
In cell enumeration assays, we found that T-cad over-
expression increased proliferation rates of both HUVEC
and hSMC as compared to their respective empty vector
and LacZ controls (Fig. 4). Although moderate (approxi-
mately 1.5-fold increase above controls), the effect was
reproducible and significant (P at least < 0.05). DNA
synthesis assay confirmed this effect whereby, compared
with empty vector and LacZ controls, HUVEC and hSMC
overexpressing T-cad incorporated significantly more [3H]-
thymidine (P at least < 0.01 at all tested FCS concentra-
tions; Fig. 4).
3.4. Influence of T-cad overexpression on cell-cycle
progression
Infected cells were synchronized in G1/G0, released
from growth-arrest and analysed for progression through
the cell cycle both by immunoblotting of cell-cycle-phaseFig. 4. Cell growth is increased in T-cad overexpressing hSMC and HUVEC. Cel
bars, Z) or T-cad cDNA (filled bars, T+) were compared with respect to their pro
panels). Blots inset illustrate stability of T-cad overexpression in T+ cells during the
experiments were 2% and 10% for HUVEC and hSMC, respectively. Six and thre
synthesis, respectively. Statistical analysis was performed by One-way ANOVA
significant differences (*P < 0.05, **P at least < 0.01) between cells overexpressin
did not differ.specific markers and flow cytometry. In both HUVEC
(Fig. 5) and hSMC (Fig. 6) overexpressing T-cad, the
induction of cyclin D occurred more rapidly indicating a
more rapid entry into early S-phase. Induction of the S-
phase markers, PCNA and E2F1, as well as the M-phase
marker cyclin B also occurred earlier and reached higher
levels in T-cad overexpressing cells. Flow cytometry
confirmed the more rapid cycle progression in T-cad-
overexpressing cells whereby both the % of BrdU-positive
cells, and % of cells in S-phase and G2/M phase was
significantly greater (P at least < 0.01) than in control
cells (Table 1).4. Discussion
The role for T-cad in regulation of cell proliferation has
mostly been studied in cancer. Similarly to classical cadher-
ins, T-cad expression was found to be decreased or absent in
some tumour samples and cancer cell lines, including breast,
lung, colon, neuroblastoma, prostate, bladder, melanoma
carcinomas (reviewed in Ref. [13]). Overexpression of T-
cad in neuroblastoma cells inhibited cell invasion and
growth responses to EGF [22], while overexpression in
C6 glioma cells was associated with decreased cell motility
and a reduction of proliferation that involved G2 phase arrestls infected with empty-vector (open bars, E), vector carrying LacZ (striped
liferation rates by cell enumeration (left panels) and DNA synthesis (right
course of growth analysis. FCS concentrations used in the cell enumeration
e independent experiments were performed for cell enumeration and DNA
followed by post hoc Bonferroni’s multiple comparison. Asterisks indicate
g T-cad and either empty-vector or LacZ controls. Empty and LacZ controls
 Fig. 5. Cell-cycle progression in control and T-cad overexpressing HUVEC. Lysates of HUVEC infected with empty vector (E, open circles) and vectors
carrying LacZ (Z, open triangles) or T-cad cDNA (T, filled circles) prepared at consecutive intervals after release from growth-arrest were analysed by
immunoblotting. Data for changes in expression (relative to 0 time) are given as meanF S.D. (n= 3), except for Ga (mean values only) for which there was
sufficient lysate for analysis in only two of the experiments.
D. Ivanov et al. / Cardiovascular Research 64 (2004) 132–143 139[23]. In contrast, overexpression of T-cad was demonstrated
in astrocytoma tumours with heterozygosity or inactivation
of the neurofibromatosis 1 tumour suppressor gene [24] and
in tumorigenic liver tissue [25]. High expression of T-cad
was also found in the MAHLAVU hepatocellular carcinoma
cell line, whereas it was absent in HepG2, PLC/PRF/C,
TONG, HA22TNGH hepatocellular carcinoma cell lines[25]. T-cad is also expressed in osteosarcoma cell lines
[26]. Thus, the influence of T-cad on cell proliferation may
vary between cell types.
A positive relationship between T-cad upregulation and
stimulation of vascular cell growth and motility first
emerged through immunohistochemical demonstration of
increased T-cad levels on SMC and EC in proliferative
Fig. 6. Analysis of cell-cycle markers in control and T-cad overexpressing hSMC. Lysates of hSMC infected with empty vector (E, open circles) and vectors
carrying LacZ (Z, open triangles) or T-cad cDNA (T, filled circles) prepared at consecutive intervals after release from growth-arrest were analysed by
immunoblotting. Three independent experiments were performed and data reflect changes in expression relative to 0 time.
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[8,14,15]. This hypothesis was later supported both by
observations of elevated T-cad expression during tumour
angiogenesis [15], and in vitro studies showing that T-cad
induces cell detachment, promotes phenotypic modulation
of EC to a polarized pro-migratory phenotype and facilitates
directed cell migration [12]. These studies strongly support
a positive relationship between T-cad and vascular cell
motility/migration. However, the relationship between T-
cad and cell proliferation was unclear. T-cad levels were
higher in sparsely seeded rSMC and decreased when
cultures reached confluency suggesting that T-cad is upre-
gulated in actively growing cells [18]. Paradoxically, serum-starvation of rSMC for 48 h also caused T-cad upregulation
on the cell surface [18]. Interpretation here is confounded
by the induction of apoptosis (after 48-h serum-starvation in
rSMC), a condition where T-cad expression is also altered
and possibly contributes to cell survival (unpublished
observations, manuscript in preparation). To clarify the
relationship between T-cad and cell proliferation, the pres-
ent study specifically examined how T-cad levels change in
proliferating cells during the cell cycle, and whether over-
expression of T-cad may in its turn influence vascular cell
growth rates.
Cell cycle associated T-cad expression in HUVEC and
SMC was assessed using different experimental protocols:
Table 1
T-cad overexpression promotes cell-cycle progression
Cell-cycle-phase distribution of cells (%)
G1/G0 S G2/M Total
BrdU-positive
HUVEC-empty 70.5F 2.3 6.7F 3.4 19.6F 1.2 26.1F 2.8
HUVEC-T-cad 56.9F 7.1* 13.0F 2.4* 30.0F 4.5* 41.0F 5.6*
hSMC-empty 80.2F 1.9 7.6F 2.9 12.1F 0.6 18.3F 2.1
hSMC-T-cad 70.4F 1.1* 11.4F 1.7* 19.8F 2.6* 29.8F 3.6*
95–98% of cells were in G1/G0 and 1–3% were BrdU-positive at growth-
arrest. FACS analysis after double PI and BrdU staining was at 36 h after
release from growth-arrest.
*P< 0.01 for T-cad vs. empty.
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released from growth-arrest; (2) cells were synchronized
in early S-phase or M-phase by treatment with hydroxyurea
or colchicine, respectively; (3) cells from exponentially
growing cultures were sorted into different stages of the
cycle by FACS. All protocols yielded similar results,
namely T-cad protein levels are increased subsequent to
entry into early S-phase and remain elevated through S-
phase and M-phase. Comparison of proliferation rates and
cell-cycle characteristics of EC and SMC overexpressing T-
cad with empty vector or LacZ controls shows that T-cad
stimulates proliferation. Together, the data identify T-cad as
a growth-promotory molecule for vascular cells. Although
increases in cell number in T-cad-overexpressing cells never
exceeded two-fold as compared to controls, this mild
stimulation may have important consequences for cell
behaviour in vivo where vascular cells, even after vessel
injury leading to intimal thickening [27], have low prolif-
eration rates.
Although the mechanisms of T-cad-dependent stimula-
tion of vascular cell growth have yet to be elucidated, one
may speculate on some relationship to the anti-adhesive
properties of T-cad [12]. Repetitive attachment and detach-
ment during the cell cycle is critical to proliferation of
normal adherent cells. Among molecular mechanisms, me-
diating cell-cycle-dependent decrease in adhesiveness is
dephosphorylation of focal adhesion kinase on tyrosine
residues and phosphorylation on serine/threonine which
leads to disassembly of the FAK/p130Cas/c-Src signalling
complex and inhibition of focal adhesion formation until the
post-mitotic spreading [28]. The marked decrease in expres-
sion of classical VE- and N-cadherins shown herein for
colchicine-treated cells, which contrasts with the increase in
T-cad, could reflect a need for the cell to lose contacts with
its neighbours before cytokinesis. A similar observation has
been made for classical E-cadherin, which was lost from
cell–cell adhesion sites during mitosis [29]. It is plausible to
attribute a distinct function to T-cad, namely to facilitate
transition of the cell from an attached to a detached state
during cell division. The anti-adhesive influence of T-cad
may also contribute to pathological vascular tissue remod-
elling, since decreased cell adhesion to the substratumfavours cell phenotypic modulation and improves the ability
of a cell to respond to growth stimuli at the site of injury.
Promotion of vascular cell proliferation by T-cad may
seem paradoxical in terms of the traditional concept of
inhibitory influences of cadherin-dependent cell–cell inter-
actions on cell growth. This concept emerged largely through
studies on classical E-cadherin showing that its downregula-
tion and/or impaired function allow malignant cells to be-
come unresponsive to contact inhibition, acquire a motile and
proliferative phenotype, escape from their site of origin, and
finally to invade and metastasize [30]. The growth inhibitory
effect is believed to relate to the capacity of cadherins to link
h-catenin at the membrane thus limiting its nuclear translo-
cation and abolishing its action as oncogene [31]. In vascular
tissue, similar stabilizing functions are attributed to VE-
cadherin. VE-cadherin expression and clustering at intercel-
lular junctions can block the proliferative response of EC to
VEGF via recruitment of VEGFR-2 to VE-cadherin–h-
catenin complex and resultant inhibition of VEGFR-2 phos-
phorylation [32]. Disruption of VE-cadherin junctions in EC
results in increased VEGF production [33]. Growth factor
treatment, in its turn, may inhibit cell–cell adhesion by
downregulation of VE-cadherin and catenins [34] or tyrosine
phosphorylation of VE-cadherin complex [35].
However, a growing body of data suggests that some
cadherins, including N- and P-cadherins, do not conform to
traditional concepts of growth inhibitory functions for
cadherins. For example, a high P-cadherin level correlates
with higher proliferation rates in breast cancer [36] and a
splice variant of cad-11 promotes invasion of breast cancer
cells [37]. The role for N-cadherin in regulation of cell
growth is controversial. N-cadherin induces contact inhibi-
tion in CHO cells [38], is downregulated in adrenocortical
carcinoma [39], in haemangioma-derived cell line EOMA
[40] and in SMC after stimulation of cell proliferation [41].
However, other studies demonstrate upregulation of N-
cadherin in malignant pheochromocytoma [39] and in
SMC during neointima formation in experimental resteno-
sis, as well as an ability of anti-N-cadherin blocking
antibody to reduce migration rates in vitro [42]. During
melanoma development, loss of functional E-cadherin
accompanies gain of N-cadherin expression, and N-cadherin
promotes migration of melanocytic cells [43]. In breast
cancer cell lines, N-cadherin stimulates motility and growth
even in the presence of the normally growth-suppressive E-
cadherin [44].
The present study identifies T-cad as another member of
cadherin family which can stimulate proliferation in some
cell types. T-cad-promoted proliferation in vascular cells T-
cad may contribute to progression of vascular disorders
such as atherosclerosis, restenosis and tumour angiogenesis.
Functional differences between T-cad and the growth-inhib-
itory E- or VE-cadherins may be partly attributed to the
atypical structure of T-cad molecule. The absence of trans-
membrane and cytoplasmic domains excludes direct inter-
action of T-cad with the catenin pathway and implies
D. Ivanov et al. / Cardiovascular Research 64 (2004) 132–143142existence of other mediatory molecular partners. T-cad is
enriched in lipid raft domains of plasma membrane [45] that
also contain other GPI-anchored proteins, Src family
kinases, Ras-protein, protein kinase C, MAP-kinase and
GTP-binding proteins [46]. Conceivably some of these
molecules may serve as adaptors coupling extracellular T-
cad to intracellular signal transduction systems involved in
stimulation of vascular cell proliferation.Acknowledgements
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